Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine nasal spray monotherapy in adult treatment-resistant depression (China, Phase 3)
CTR20263138Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20263138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263138.